Core Viewpoint - The article emphasizes the importance of confirming the sustainability of stock trends for successful short-term investing, highlighting that price movements should be supported by strong fundamentals and positive earnings estimates [1][2]. Group 1: Stock Performance - iRadimed (IRMD) has shown a solid price increase of 28.8% over the past 12 weeks, indicating strong investor interest [4]. - The stock has also maintained a price increase of 13.8% over the last four weeks, suggesting that the upward trend is still intact [5]. - Currently, IRMD is trading at 94.9% of its 52-week high-low range, indicating a potential breakout [6]. Group 2: Fundamental Strength - IRMD holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises [6]. - The stock has an Average Broker Recommendation of 1 (Strong Buy), reflecting high optimism from the brokerage community regarding its near-term price performance [7]. Group 3: Investment Strategy - The "Recent Price Strength" screen is a useful tool for investors to identify stocks like IRMD that are on an uptrend supported by strong fundamentals [3]. - The article suggests that there are several other stocks passing through this screen, providing additional investment opportunities [8].

Core Insights - Iradimed Corporation has been recognized as one of Fortune's 100 Fastest Growing Companies for 2024, ranking 61st on the list, which highlights the company's growth in revenue, profits, and stock returns [2] Company Overview - Iradimed Corporation specializes in developing innovative MRI-compatible medical devices, including a non-magnetic intravenous infusion pump system and patient vital signs monitoring systems designed for MRI procedures [4][5] - The company is the only known provider of a non-magnetic IV infusion pump system, which is crucial for safely delivering anesthesia and IV fluids during MRI procedures [5][6] Product Details - The MRidium® MRI-compatible IV infusion pump system features a non-magnetic ultrasonic motor and non-ferrous parts, ensuring safe operation in the presence of MRI's powerful magnetic fields [5] - The 3880 MRI-compatible patient vital signs monitoring system is designed to operate in magnetic fields up to 30,000 gauss, allowing for continuous monitoring of critically ill patients during MRI scans [7] - The 3880 system includes advanced features such as wireless ECG, SpO2 monitoring, non-magnetic respiratory CO2 measurement, and optional multi-gas anesthetic agent monitoring [7]

Financial Data and Key Metrics Changes - Revenue for Q3 2024 was $18.3 million, an increase of 11% compared to Q3 2023, driven by strong IV pump sales [11] - Gross profit margin was 77.4%, slightly down from 77.8% in Q3 2023 [12] - GAAP diluted earnings per share were $0.40, unchanged from Q3 2023, while non-GAAP diluted earnings per share were also stable at $0.43 [14] - Operating expenses increased to $8.4 million, or 46% of revenue, compared to $6.9 million, or 42% of revenue, in Q3 2023 [13] - Cash from operations was $9.1 million, significantly up from $1.4 million in the same period last year [15] Business Line Data and Key Metrics Changes - Domestic sales increased by 9% to $15.2 million, while international sales rose by 22% to $3.1 million [11] - Device revenue increased by 10% to $13 million, with pump revenue up by 78% [12] - Revenue from disposables and services increased by 12% to $4.7 million, while maintenance contracts remained stable at $600,000 [12] Market Data and Key Metrics Changes - Domestic revenue accounted for approximately 83% of total revenue in Q3 2024, down from 84% in Q3 2023 [12] - The company has a strong backlog, primarily driven by pump sales, but monitors also contribute significantly [20] Company Strategy and Development Direction - The company is focused on obtaining FDA clearance for a new pump, with expectations for initial revenue in Q4 2025 [7][10] - Plans to emphasize monitor sales in 2025 as the transition to the new pump occurs, anticipating a temporary dip in pump revenue [19][29] - The new headquarters construction is on schedule, expected to be completed by May 2025, coinciding with the new pump launch [8] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in maintaining revenue levels despite anticipated changes in product mix due to the new pump launch [19] - The company expects to end 2024 strongly, with guidance for Q4 revenue between $18.8 million and $19.2 million [9][10] - Management acknowledged the challenges of explosive growth expected from the new pump and is preparing for it [35] Other Important Information - Operating expenses were impacted by increased sales commissions and regulatory costs, which management plans to balance in future quarters [21][23] - Free cash flow for Q3 2024 was $5.1 million, up from $954,000 in Q3 2023, indicating improved efficiency in working capital management [16] Q&A Session Summary Question: How should growth by business line be viewed, especially with IV pumps being a standout? - Management anticipates a dip in old pump sales as they transition to the new pump, while focusing on monitor sales to fill the gap [17][19] Question: What is the composition of the current backlog? - The backlog remains strong, primarily due to pump sales, but monitors also contribute significantly [20] Question: Can you elaborate on operating expenses and their growth relative to revenue? - The increase in operating expenses was largely due to higher sales commissions, reflecting a more balanced approach to sales compensation [21][23] Question: If FDA approval comes earlier, will it impact the new pump's launch? - Management indicated that even with earlier approval, the launch plans would not be significantly accelerated [26] Question: What are the plans for expanding the monitor business? - The company plans to adjust sales compensation to emphasize monitor sales more effectively in 2025 [27][29] Question: How is the sales force structured for the new pump and monitor sales? - Management is considering expanding the sales team and territories to accommodate growth from the new pump while maintaining monitor sales [32][34]

Revenue and Income - Revenue for the three months ended September 30, 2024, was $18,325,959, representing an increase of 11% compared to $16,504,640 for the same period in 2023[11]. - Net income for the three months ended September 30, 2024, was $5,049,491, slightly down from $5,067,180 in the same quarter of 2023[11]. - Net income for the nine months ended September 30, 2024, was $14,087,248, compared to $12,653,090 for the same period in 2023, reflecting a growth of approximately 11%[16]. - Total revenue for the nine months ended September 30, 2024, reached $53,852,954, a 12.5% increase compared to $48,110,120 for the same period in 2023[26]. - Basic net income per share remained stable at $0.40 for both the three months ended September 30, 2024, and 2023[11]. - Diluted net income per share for the nine months ended September 30, 2024, was $1.10, compared to $0.99 for the same period in 2023[32]. Expenses - Operating expenses for the three months ended September 30, 2024, totaled $8,402,586, an increase of 21% from $6,932,044 in the prior year[11]. - Total operating expenses for the nine months ended September 30, 2024, were $25,424,512, up from $21,869,704 in 2023, reflecting an increase of 16.5%[11]. - Research and development expenses increased to $639,467 for the three months ended September 30, 2024, compared to $452,555 in 2023, reflecting a rise of 41%[11]. - Sales and marketing expenses increased by $0.9 million, or 31.0%, to $3.8 million for the three months ended September 30, 2024[81]. - General and administrative expenses increased by $0.4 million, or 11.1%, to $4.0 million for the three months ended September 30, 2024[79]. Cash Flow and Liquidity - Cash and cash equivalents at the end of the period increased to $51,721,051 from $46,745,124, marking an increase of about 10%[16]. - Operating cash flow for the nine months ended September 30, 2024, was $19,637,394, significantly higher than $9,552,532 for the same period in 2023[16]. - Cash provided by operating activities increased by $10.0 million to $19.6 million for the nine months ended September 30, 2024, compared to $9.6 million for the same period in 2023[94]. - Cash used in investing activities decreased by $1.6 million to $5.8 million for the nine months ended September 30, 2024, compared to $7.4 million for the same period in 2023[95]. - Cash used in financing activities decreased by $1.5 million to $11.9 million for the nine months ended September 30, 2024, compared to approximately $13.4 million for the same period in 2023[96]. Revenue Breakdown - Revenue from the United States for the three months ended September 30, 2024, was $15,207,195, up from $13,948,368 in the same period of 2023, indicating a growth of approximately 9%[26]. - International revenue for the three months ended September 30, 2024, was $3,118,764, compared to $2,556,272 in the same period of 2023, reflecting a growth of about 22%[26]. - Revenue from sales in the U.S. increased by $1.3 million, or 9.4%, to $15.2 million for the three months ended September 30, 2024[70]. - Revenue from sales of devices increased by $1.2 million, or 10.4%, to $13.0 million for the three months ended September 30, 2024[71]. - Revenue from sales of disposables, services, and other increased by $0.5 million, or 11.9%, to $4.7 million for the three months ended September 30, 2024[72]. Stockholder Equity and Dividends - The total stockholders' equity as of September 30, 2024, was $83,432,625, an increase from $74,568,000 as of September 30, 2023[13]. - The company paid dividends of $11,776,128 during the nine months ended September 30, 2024, compared to $13,222,907 in the same period of 2023[16]. - The company declared a regular quarterly cash dividend of $0.15 per share on October 30, 2024, to be paid on November 25, 2024[53]. Future Outlook - The company anticipates continued growth in revenue driven by new product introductions and market expansion efforts[3]. - Future performance may be impacted by regulatory approvals and market acceptance of new products[3]. - The company expects higher revenue for the remainder of 2024 compared to the same period in 2023, primarily due to increased sales of medical devices and related services[63]. Inventory and Assets - Total inventory as of September 30, 2024, was $11,251,549, down from $12,821,194 at the end of 2023[34]. - Total property and equipment, net, increased to $14,155,985 as of September 30, 2024, from $9,288,625 as of December 31, 2023[36]. - The company recorded a net cash used in investing activities of $5,760,057 for the nine months ended September 30, 2024, compared to $7,374,351 in the same period of 2023[16]. Tax and Compliance - The company recorded a provision for income tax expense of $1,368,830 for the three months ended September 30, 2024, with an effective tax rate of 21.3%[42]. - The effective tax rate for the three months ended September 30, 2024, was 21.3%, compared to 20.9% for the same period in 2023[42][43]. - For the nine months ended September 30, 2024, the company recorded a provision for income tax expense of $3,843,834, with an effective tax rate of 21.4%[88].

分组1 - iRadimed reported quarterly earnings of $0.43 per share, exceeding the Zacks Consensus Estimate of $0.39 per share, with an earnings surprise of 10.26% [1] - The company achieved revenues of $18.33 million for the quarter ended September 2024, surpassing the Zacks Consensus Estimate by 0.72%, and showing an increase from $16.51 million year-over-year [2] - iRadimed has surpassed consensus EPS estimates three times over the last four quarters, indicating a positive trend in earnings performance [2] 分组2 - The stock has gained approximately 11.5% since the beginning of the year, while the S&P 500 has increased by 21.9%, suggesting underperformance relative to the broader market [3] - The current consensus EPS estimate for the upcoming quarter is $0.43 on revenues of $20.02 million, and for the current fiscal year, it is $1.61 on revenues of $73.74 million [7] - The Medical - Instruments industry, to which iRadimed belongs, is currently ranked in the top 24% of over 250 Zacks industries, indicating a favorable industry outlook [8]

Exhibit 99.1 IRADIMED CORPORATION Announces Third Quarter of 2024 Financial Results and the Declaration of its Regular Quarterly Cash Dividend of $0.15 Per Share ● Reports record revenue of $18.3 million for the third quarter of 2024, an increase of $1.8 million or 11% over the comparable period 2023. ● Reports GAAP diluted EPS of $0.40 and Non-GAAP diluted EPS of $0.43 for the third quarter of 2024. ● Raising year end guidance on GAAP diluted earnings per share to $1.49 to $1.52 from $1.37 to $1.47, and No ...

WINTER SPRINGS, Fla., Oct. 24, 2024 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD) announced today that the Company will release its 2024 third quarter financial results before the market opens on Thursday, October 31, 2024. Iradimed management will host a conference call the same day beginning at 11:00 a.m. Eastern Time to discuss those results and to answer questions. Individuals interested in participating in the conference call may do so by registering here, https://register.vevent.com/register ...

WINTER SPRINGS, Fla., Oct. 03, 2024 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION ("Iradimed") (NASDAQ: IRMD), a leading provider of innovative magnetic resonance imaging (MRI) compatible medical devices, announced today that it will participate in the 3rd Annual ROTH Healthcare Opportunities Conference. Iradimed's CFO, Jack Glenn, will host one-on-one meetings with investors at the 3rd Annual ROTH Healthcare Opportunities Conference at the Metropolitan Club in New York on October 9, 2024. About IRADIMED CORPORA ...

WINTER SPRINGS, Fla., Sept. 10, 2024 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION ("Iradimed") (NASDAQ: IRMD), a leading provider of innovative magnetic resonance imaging (MRI) compatible medical devices, announced today that the Company will be participating in the Lake Street 8th Annual Best Ideas Growth "Big 8" Conference. Iradimed management will host one-on-one meetings between company management and investors at the Lake Street 8th Annual Best Ideas Growth "Big 8" Conference at the Yale Club in New York o ...

IRadimed (IRMD) came out with quarterly earnings of $0.42 per share, beating the Zacks Consensus Estimate of $0.36 per share. This compares to earnings of $0.36 per share a year ago. These figures are adjusted for nonrecurring items. This quarterly report represents an earnings surprise of 16.67%. A quarter ago, it was expected that this maker of IV devices that can be used in MRI machines would post earnings of $0.34 per share when it actually produced earnings of $0.36, delivering a surprise of 5.88%. Ove ...